Literature DB >> 24119542

Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia.

Elise Cuyvers1, Karolien Bettens, Stéphanie Philtjens, Tim Van Langenhove, Ilse Gijselinck, Julie van der Zee, Sebastiaan Engelborghs, Mathieu Vandenbulcke, Jasper Van Dongen, Nathalie Geerts, Githa Maes, Maria Mattheijssens, Karin Peeters, Patrick Cras, Rik Vandenberghe, Peter P De Deyn, Christine Van Broeckhoven, Marc Cruts, Kristel Sleegers.   

Abstract

Homozygous mutations in exon 2 of TREM2, a gene involved in Nasu-Hakola disease, can cause frontotemporal dementia (FTD). Moreover, a rare TREM2 exon 2 variant (p.R47H) was reported to increase the risk of Alzheimer's disease (AD) with an odds ratio as strong as that for APOEε4. We systematically screened the TREM2 coding region within a Belgian study on neurodegenerative brain diseases (1216 AD patients, 357 FTD patients, and 1094 controls). We observed an enrichment of rare variants across TREM2 in both AD and FTD patients compared to controls, most notably in the extracellular IgV-set domain (relative risk = 3.84 [95% confidence interval = 1.29-11.44]; p = 0.009 for AD; relative risk = 6.19 [95% confidence interval = 1.86-20.61]; p = 0.0007 for FTD). None of the rare variants individually reached significant association, but the frequency of p.R47H was increased ~ 3-fold in both AD and FTD patients compared to controls, in line with previous reports. Meta-analysis including 11 previously screened AD cohorts confirmed the association of p.R47H with AD (p = 2.93×10(-17)). Our data corroborate and extend previous findings to include an increased frequency of rare heterozygous TREM2 variations in AD and FTD, and show that TREM2 variants may play a role in neurodegenerative diseases in general.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Frontotemporal dementia; IgV-set domain; Meta-analysis; Rare variants; TREM2

Mesh:

Substances:

Year:  2013        PMID: 24119542     DOI: 10.1016/j.neurobiolaging.2013.09.009

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  78 in total

1.  Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.

Authors:  Laura Piccio; Yuetiva Deming; Jorge L Del-Águila; Laura Ghezzi; David M Holtzman; Anne M Fagan; Chiara Fenoglio; Daniela Galimberti; Barbara Borroni; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2016-01-11       Impact factor: 17.088

2.  The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease.

Authors:  Megan M Varnum; Tomomi Kiyota; Kaitlin L Ingraham; Seiko Ikezu; Tsuneya Ikezu
Journal:  Neurobiol Aging       Date:  2015-08-01       Impact factor: 4.673

Review 3.  TREM2 variants: new keys to decipher Alzheimer disease pathogenesis.

Authors:  Marco Colonna; Yaming Wang
Journal:  Nat Rev Neurosci       Date:  2016-02-25       Impact factor: 34.870

Review 4.  Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?

Authors:  Yuetiva Deming; Zeran Li; Bruno A Benitez; Carlos Cruchaga
Journal:  Expert Opin Ther Targets       Date:  2018-06-20       Impact factor: 6.902

5.  TREM2 variants and risk of Alzheimer's disease: a meta-analysis.

Authors:  Yanjun Lu; Wei Liu; Xiong Wang
Journal:  Neurol Sci       Date:  2015-06-03       Impact factor: 3.307

6.  Genetic Analysis of TREM2 Variants in Tunisian Patients with Alzheimer's Disease.

Authors:  Zied Landoulsi; Mouna Ben Djebara; Imen Kacem; Youssef Sidhom; Rym Kefi; Sonia Abdelhak; Amina Gargouri-Berrechid; Riadh Gouider
Journal:  Med Princ Pract       Date:  2018-05-03       Impact factor: 1.927

7.  The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia.

Authors:  Panos Roussos; Pavel Katsel; Peter Fam; Weilun Tan; Dushyant P Purohit; Vahram Haroutunian
Journal:  Alzheimers Dement       Date:  2014-12-09       Impact factor: 21.566

Review 8.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

9.  CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.

Authors:  Boris-Stephan Rauchmann; Thomas Schneider-Axmann; Panagiotis Alexopoulos; Robert Perneczky
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

Review 10.  Alzheimer's disease genetics: from the bench to the clinic.

Authors:  Celeste M Karch; Carlos Cruchaga; Alison M Goate
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.